Skip to Content

Join the 'Trizivir' group to help and get support from people like you.

Trizivir News

CDC: Black Americans With HIV Still Less Likely to Get Ongoing Medical Care

Posted 14 hours ago by Drugs.com

FRIDAY, Feb. 5, 2016 – While HIV diagnoses dropped significantly over the past decade in the United States, blacks with HIV are less likely than whites or Hispanics to receive routine, ongoing care, according to the U.S. Centers for Disease Control and Prevention. From 2005 to 2014, annual HIV diagnoses fell 19 percent in the United States. Infections among black women dropped 42 percent during this period. Despite this progress in the fight against HIV, racial disparities persist, the CDC found. While black people make up 12 percent of the U.S. population, they accounted for nearly half of all HIV diagnoses in 2014. "CDC has been working for many years to eliminate the HIV disparities that exist within the black community," Dr. Eugene McCray, director of the CDC's Division of HIV/AIDS Prevention, said in an agency news release. "While we are seeing signs of success, we must continue ... Read more

Related support groups: Harvoni, HIV Infection, Atripla, Tamiflu, Incivek, Pre-Exposure Prophylaxis, Truvada, Triumeq, Baraclude, Stribild, Victrelis, Complera, Oseltamivir, Kaletra, Viread, Tenofovir, Norvir, Entecavir, Telaprevir, Boceprevir

HIV Can Persist in Body Despite Drug Therapy

Posted 10 days ago by Drugs.com

WEDNESDAY, Jan. 27, 2016 – Even when blood tests of HIV patients on antiretroviral drugs show no sign of the AIDS-causing virus, it can still be replicating in lymphoid tissue, researchers report. The study offers important new insight into how HIV persists in the body despite treatment with the powerful drugs, according to the team of international researchers led by Northwestern University's Feinberg School of Medicine in Chicago. To reach their finding, they examined viral sequences in samples of lymph node and blood cells from three HIV-infected patients who had no detectable virus in their blood. And what they found was that a viral reservoir in lymphoid tissue, which scientists believed held long-lived infected cells in a resting state, was being constantly replenished with infected cells. "The challenge is to deliver drugs at clinically effective concentrations to where the ... Read more

Related support groups: Harvoni, HIV Infection, Atripla, Sovaldi, Incivek, Pre-Exposure Prophylaxis, Truvada, Triumeq, Baraclude, Stribild, Complera, Victrelis, Sofosbuvir, Kaletra, Tenofovir, Viread, Norvir, Entecavir, Diagnosis and Investigation, Telaprevir

FDA Lifts Ban on Blood Donations by Gay Men

Posted 21 Dec 2015 by Drugs.com

MONDAY, Dec. 21, 2015 – Gay and bisexual men who have abstained from sex for one year will now be allowed to donate blood in the United States. The new policy, announced Monday by the U.S. Food and Drug Administration, reverses a three-decades-old ban on donations from this group of men that traces back to the start of the AIDS epidemic. "The FDA's responsibility is to maintain a high level of blood product safety for people whose lives depend on it," FDA Acting Commissioner Stephen Ostroff said in an agency news release. "We have taken great care to ensure this policy revision is backed by sound science and continues to protect our blood supply." The FDA said it was changing its policy based on data from other countries that show allowing such donations would not increase the risk of HIV-tainted blood entering America's blood supply. FDA officials have estimated that about half of the ... Read more

Related support groups: Blood Disorders, Bleeding Disorder, Harvoni, HIV Infection, Valtrex, Acyclovir, Anemia, Atripla, Tamiflu, Ribavirin, Valacyclovir, Incivek, Pre-Exposure Prophylaxis, Zovirax, Blood Transfusion, Truvada, Triumeq, Baraclude, Stribild, Victrelis

Risky Sexual Behaviors Put Many Young Gay Men at Risk of HIV: Study

Posted 7 Dec 2015 by Drugs.com

MONDAY, Dec. 7, 2015 – Young American gay and bisexual men who have detectable blood levels of HIV – the virus that causes AIDS – are also more likely to engage in risky sexual behavior that might spread the virus, a new study has found. "While many of these young men are engaged in care, and success stories are many, we still have work to do to reduce the rate of new infections," study author Patrick Wilson, an assistant professor of sociomedical sciences at Columbia University's Mailman School of Public Health in New York City, said in a university news release. Different strategies to help prevent HIV infections and promote safe sex are needed for this group, his team wrote in the Dec. 7 issue of the journal JAMA Pediatrics. According to the researchers, young men between the ages of 13 and 29 who are gay or bisexual are particularly vulnerable to infection with HIV and now ... Read more

Related support groups: Birth Control, Contraception, Emergency Contraception, Harvoni, HIV Infection, Postcoital Contraception, Atripla, Incivek, Pre-Exposure Prophylaxis, Truvada, Triumeq, Baraclude, Stribild, Complera, Victrelis, Kaletra, Viread, Tenofovir, Norvir, Entecavir

HIV Rates Fall, But Not All Groups Benefit, U.S. Study Finds

Posted 7 Dec 2015 by Drugs.com

MONDAY, Dec. 7, 2015 – The number of Americans diagnosed with HIV each year declined by about one-fifth during the past decade, but not all groups saw drops in prevalence, a federal government study shows. Between 2005 and 2014, the overall annual number of HIV diagnoses fell 19 percent – from nearly 48,800 to just over 39,700 a year. The drop was led by a 63 percent decline among injection drug users, a 42 percent drop among black women, and a 35 percent decrease among heterosexuals. However, annual HIV diagnoses among gay and bisexual men actually rose about 6 percent during the study period, from about 25,000 to just over 26,600 a year, although they recently stabilized at less than a 1 percent increase a year. The increase in HIV diagnoses among gay and bisexual men was driven largely by blacks and Hispanics, the U.S. Centers for Disease Control and Prevention report found. HIV ... Read more

Related support groups: Harvoni, HIV Infection, Atripla, Incivek, Truvada, Triumeq, Baraclude, Stribild, Victrelis, Complera, Kaletra, Viread, Tenofovir, Norvir, Entecavir, Diagnosis and Investigation, Telaprevir, Nevirapine, Ledipasvir/sofosbuvir, Reyataz

HIV Therapy May Also Lower Risk for Hepatitis B, Study Says

Posted 12 Oct 2015 by Drugs.com

MONDAY, Oct. 12, 2015 – Not only does effective HIV therapy thwart the AIDS-causing virus, it may also reduce the risk for hepatitis B infection, a new study says. "What this means to us is that effective HIV therapy appears to restore an impairment in the immune response that protects someone with HIV from acquiring hepatitis B infection," study senior author Dr. Chloe Thio, a professor of medicine at Johns Hopkins University School of Medicine, said in a university news release. The study, published in the October issue of Annals of Internal Medicine, involved 2,400 gay and bisexual men who were enrolled in the Multicenter AIDS Cohort Study. Researchers found that the men successfully treated with HIV therapy had the same risk for hepatitis B infection as the men who did not have HIV. Hepatitis B is a virus that can damage the liver. The study showed HIV-positive men on HIV therapy ... Read more

Related support groups: Harvoni, HIV Infection, Valtrex, Acyclovir, Atripla, Hepatitis B, Ribavirin, Sovaldi, Valacyclovir, Incivek, Pre-Exposure Prophylaxis, Zovirax, Truvada, Pegasys, Triumeq, Baraclude, Stribild, Complera, Victrelis, Famciclovir

Many U.S. AIDS Patients Still Die When 'Opportunistic' Infections Strike

Posted 1 Jul 2015 by Drugs.com

WEDNESDAY, July 1, 2015 – Even after the advent of powerful medications for suppressing HIV, a new study finds that more than one-third of people in San Francisco who were diagnosed with an AIDS-related infection died within five years. "The main cause of mortality arises from people stopping treatment entirely," said Dr. Robert Grant, a professor at the University of California, San Francisco, who reviewed the findings but was not involved in the research. When HIV treatment lapses, so-called "opportunistic" infections and illnesses can arise, posing a real threat to patients' health, he explained. The bottom line, according to Grant, is that there is still "a long way to go" in prolonging the lives of Americans with HIV/AIDS. The new study was led by Dr. Sandra Schwarcz, associate professor of epidemiology and biostatistics at the University of California, San Francisco. She and her ... Read more

Related support groups: Harvoni, HIV Infection, Atripla, Tamiflu, Sovaldi, Incivek, Pre-Exposure Prophylaxis, Truvada, Triumeq, Baraclude, Stribild, Complera, Victrelis, Mycobacterium avium-intracellulare, Mycobacterium avium-intracellulare - Treatment, Oseltamivir, Sofosbuvir, Kaletra, Viread, Tenofovir

Sequence of Shots May Lead to Effective HIV Vaccine, Mouse Study Finds

Posted 25 Jun 2015 by Drugs.com

THURSDAY, June 25, 2015 – It's unlikely that a single vaccine would ever enable the body to neutralize the HIV virus, but a sequence of immunizations might hold the key, a new mouse study suggests. The immune system could be guided in a series of steps to develop a special type of HIV-fighting antibody, a team of researchers said. Each immunization would be customized for specific stages of the immune system's response to the virus. In the end, the series of shots would result in the production of broadly neutralizing antibodies capable of fighting HIV, the authors said. "As HIV mutates in a patient, the immune system continually adapts. In some patients, this process produces broadly neutralizing antibodies, which are unusual antibodies that can bind to and neutralize a wide range of globally occurring HIV variants. These are the antibodies we want to try to elicit with a vaccine," ... Read more

Related support groups: Harvoni, HIV Infection, Atripla, Sovaldi, Incivek, Pre-Exposure Prophylaxis, Truvada, Triumeq, Baraclude, Stribild, Complera, Victrelis, Sofosbuvir, Kaletra, Viread, Tenofovir, Entecavir, Norvir, Telaprevir, Lamivudine

1 in 5 Younger Americans Tested for HIV

Posted 2 Jun 2015 by Drugs.com

TUESDAY, June 2, 2015 – Nearly one-fifth of teens and younger adults in the United States have been tested recently for HIV, federal health officials reported Tuesday. In 2011, more than 1 million Americans 13 and older had HIV, but one in seven did not know their infection status. Routine, voluntary testing is known to reduce transmission of HIV, the virus that causes AIDS, according to the U.S. Centers for Disease Control and Prevention. Researchers at the CDC's National Center for Health Statistics analyzed data from 5,600 females and more than 4,800 males, ages 15-44, who took part in the 2011-2013 National Survey of Family Growth. The researchers found that 19 percent had undergone HIV testing in the past year, an increase from 17 percent in both 2002 and 2006-2010. HIV testing rates in 2011-2013 were 22 percent for females and 16 percent for males, compared with 20 percent for ... Read more

Related support groups: Harvoni, HIV Infection, Atripla, Incivek, Pre-Exposure Prophylaxis, Truvada, Triumeq, Baraclude, Stribild, Victrelis, Complera, Kaletra, Viread, Tenofovir, Norvir, Entecavir, Diagnosis and Investigation, Telaprevir, Nevirapine, Reyataz

Global Trial Finds HIV Drugs Should Be Taken Right After Diagnosis

Posted 28 May 2015 by Drugs.com

WEDNESDAY, May 27, 2015 – People with HIV should start taking medications to battle the virus that causes AIDS as soon as they're diagnosed, a new international study finds. Scientists involved in the trial were so impressed by the health benefits of early use of HIV drugs that they shut the study down early so they could offer the medications to all participants. The findings could alter World Health Organization guidelines about the best way to treat people with HIV, experts said. Currently, WHO recommends that HIV patients not start treatment until their immune system show signs of weakening. "We now have clear-cut proof that it is of significantly greater health benefit to an HIV-infected person to start antiretroviral therapy sooner rather than later," Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, said in a statement. "Moreover, ... Read more

Related support groups: Harvoni, HIV Infection, Atripla, Tamiflu, Incivek, Truvada, Triumeq, Baraclude, Stribild, Victrelis, Complera, Oseltamivir, Kaletra, Viread, Tenofovir, Norvir, Entecavir, Telaprevir, Boceprevir, Reyataz

Experimental AIDS Vaccine Targets Hidden Virus

Posted 29 Apr 2015 by Drugs.com

WEDNESDAY, April 29, 2015 – Preliminary research suggests that an AIDS vaccine in development can ramp up the body's immune system, boosting the response to medications HIV-positive patients take. Years of research will be required to confirm that the vaccine works, and researchers don't yet have the major funding needed to continue and push the experimental vaccine toward the market. Still, there's tremendous potential, said study senior author Dr. Barbara Ensoli, director of the National AIDS Center at the National Institute of Health in Rome, Italy. "Although the results are from infected patients, the vaccine may be suitable for both healthy and HIV-infected patients," said Ensoli. So far, she said, the vaccine appears to be well tolerated, with no signs of significant side effects. A vaccine has long been the holy grail of research into AIDS and HIV, the virus that causes the ... Read more

Related support groups: Harvoni, HIV Infection, Atripla, Incivek, Truvada, Triumeq, Baraclude, Stribild, Victrelis, Complera, Kaletra, Viread, Tenofovir, Norvir, Entecavir, Telaprevir, Nevirapine, Ledipasvir/sofosbuvir, Reyataz, Lamivudine

FDA: More Than 150 Antiretroviral Drugs Available Through PEPFAR for Worldwide HIV/AIDS Relief

Posted 23 Jul 2012 by Drugs.com

July 23, 2012 – Today, U.S. Food and Drug Administration (FDA) Commissioner Margaret A. Hamburg announced the agency has approved or tentatively approved a total of 152 antiretroviral drugs in association with the President’s Emergency Plan for AIDS Relief (PEPFAR) to treat those infected with HIV/AIDS in countries that lack the tools needed to fight the AIDS epidemic. The most recent FDA actions in association with PEPFAR were tentative approvals of the following generic drugs: abacavir oral solution (Hetero Labs Ltd. Unit III, July 2, 2012) lopinavir and ritonavir oral solution (Cipla Ltd., June 29, 2012) efavirenz tablets (Edict Pharmaceuticals Private Ltd., June 25, 2012 and Micro Labs Ltd., June 20, 2012) Tentative approval means that although FDA has found that a drug product has met all required manufacturing quality, clinical safety, and efficacy requirements, it cannot be a ... Read more

Related support groups: HIV Infection, Atripla, Incivek, Baraclude, Victrelis, Tenofovir, Kaletra, Viread, Entecavir, Norvir, Telaprevir, Nevirapine, Boceprevir, Lamivudine, Reyataz, Lexiva, Norvir Soft Gelatin, Abacavir, Epivir, Hepsera

FDA MedWatch - Abacavir - Ongoing Safety Review: Possible Increased Risk of Heart Attack

Posted 2 Mar 2011 by Drugs.com

Abacavir - Ongoing Safety Review: Possible Increased Risk of Heart Attack including Ziagen, Trizivir, and Epzicom AUDIENCE: Infectious Disease ISSUE: FDA updated the public about an ongoing safety review of abacavir and a possible increased risk of heart attack. There has been conflicting information on the potential increased risk of heart attack with abacavir treatment. An increased risk of heart attack (myocardial infarction or MI) has been seen in several observational studies and one randomized controlled trial (RCT) with abacavir. However, an increased risk of heart attack has not been seen in other RCTs and the safety database maintained by the drug manufacturer. FDA conducted a meta-analysis of 26 randomized clinical trials that evaluated abacavir. This meta-analysis did not show an increased risk of MI associated with the use of abacavir. FDA will continue to communicate any ... Read more

Related support groups: Abacavir, Trizivir, Epzicom, Ziagen, Abacavir/Lamivudine, Abacavir/Lamivudine/Zidovudine

Anti-HIV Drugs May Help Prevent Spread of Virus

Posted 27 May 2010 by Drugs.com

THURSDAY, May 27 – People who are HIV-positive can lower their risk for transmitting the virus to their partners by 90 percent by taking antiretroviral drugs, new research has found. Antiretroviral drug therapy helps reduce HIV levels in the infected person's blood, which in turn makes the person less infectious to others. The drugs are commonly taken in the United States by people with HIV, the virus that causes AIDS. In the new research, published online May 26 in The Lancet, investigators studied more than 3,400 heterosexual couples in seven African countries. In each couple, one person was infected with HIV and the other was not. No one in the study was taking antiretroviral drugs. Health workers counseled the couples about preventing HIV transmission and followed up with them for two years. During that time, periodic blood tests measured HIV levels in the blood, and people were ... Read more

Related support groups: HIV Infection, Atripla, Truvada, Baraclude, Kaletra, Viread, Tenofovir, Norvir, Entecavir, Nevirapine, Reyataz, Lamivudine, Epivir, Interferon Alfa-2B/Ribavirin, Hepsera, Prezista, Combivir, Abacavir, Lexiva, Norvir Soft Gelatin

FDA Medwatch Alert: Abacavir (marketed as Ziagen) and Abacavir-containing Medications

Posted 24 Jul 2008 by Drugs.com

[Posted 07/24/2008] FDA informed healthcare professionals that serious and sometimes fatal hypersensitivity reactions (HSR) caused by abacavir therapy are significantly more common in patients with a particular human leukocyte antigen (HLA) allele, HLA-B*5701. FDA reviewed data from two studies that support a recommendation for pre-therapy screening for the presence of the HLA-B*5701 allele and the selection of alternative therapy in positive subjects. Genetic tests for HLA-B*5701 are available and all patients should be screened for the HLA-B*5701 allele before starting or restarting treatment with abacavir or abacavir-containing medications. Development of clinically suspected abacavir HSR requires immediate and permanent discontinuation of abacavir therapy in all patients, including patients negative for HLA-B*5701.[July 24, 2008 - Information for Healthcare Professionals - FDA] Read more

Related support groups: Trizivir, Epzicom, Ziagen

Ask a Question

Further Information

Related Condition Support Groups

HIV Infection, Nonoccupational Exposure

Trizivir Patient Information at Drugs.com